Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Arvinas, Inc.NASDAQ: ARVN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $60M fell 33.9% year over year, behind the -28.3% change in trailing-twelve-month research & development. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.

Context

  • Research & development amounted to 107.7% of revenue in FY2025, down 24.5 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -33.9% toward the trailing-twelve-month pace of -28.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$60M-1.8% QoQ
Last fiscal yearDec 2025
$282.9M-18.8% YoY
LTMMar 2026
$254.4M-28.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.9%——
1 year-18.8%——
3-year CAGR-3.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
282.9M USD
Year-over-year change
-18.8%
4-year CAGR
+11.9%

Research & Development vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 research & development of $254.4M is the 3rd highest of the 6 companies compared; the peer median is $153.38M.
  • Its year-over-year change of -28.3% is the lowest of 6, against a peer median of +10.2%.
  • Research & development amounts to 284.6% of revenue for ARVN, versus a peer median of 291.9%.
ARVN Competitors Peer median
Research & Development for ARVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYMRKymera Therapeutics, Inc.LTM Jun 2026$375.6M +29.1%+24.5%357.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
ARVNArvinas, Inc.LTM Mar 2026$254.4M -28.3%-3.5%284.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$153.38M +23.0%+18.5%357.1%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
Peer median (excluding ARVN) $153.38M+10.2%+18.5%291.9%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue53.6M131.4M78.5M263.4M262.6M
Cost of Revenue00005.2M
Gross Profit53.6M131.4M78.5M263.4M257.4M
Gross Margin100.0%100.0%100.0%100.0%98.0%
Research & Development180.4M315M379.7M348.2M282.9M
Selling, General & Admin61.6M79.6M100.3M165.4M89.4M
Operating Expenses242M394.6M480M513.6M372.3M
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
EBITDA(184.9M)(253.4M)(359.7M)(191.7M)(75.3M)
EBITDA Margin-345.0%-192.8%-458.2%-72.8%-28.7%
Operating Income(188.4M)(263.2M)(401.5M)(250.2M)(114.9M)
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Income1.8M12M38.8M54.8M22M
Interest Expense100K0000
Other Income / Expenses(2.6M)1.6M35.1M51.9M34.4M
Income Before Tax(191M)(261.6M)(366.4M)(198.3M)(80.5M)
Pre-Tax Margin-356.3%-199.1%-466.8%-75.3%-30.7%
Income Tax Expense020.9M900K600K300K
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Basic)(3.82)(5.31)(6.62)(2.77)(1.28)
EPS (Diluted)(3.82)(5.31)(6.62)(2.77)(1.28)
Weighted Avg Shares50M53.2M55.5M71.9M64.9M
Weighted Avg Shares (Diluted)50M53.2M55.5M71.9M64.9M

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.